Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2018-07-30 / Oncoimmunology 2018;7(12):e1474318Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-546High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-1558Dendritic cell vaccines for high-grade gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-07-26 / Ther Clin Risk Manag 2018;14:1299-1313IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
/0 Kommentare/in IOZK Veröffentlichungen /von rootVitamin D deficiency in head and neck cancer patients – prevalence, prognostic value and impact on immune function
/in International Publications, Micronutrients /von 2018-07-23 / 2018;7(9):e1476817A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-1518Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
/in International Publications, Newcastle Disease Virus, Thyroid Cancer /von 2018-07-18 / BMC Cancer 2018 Jul;18(1):746Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
/in International Publications, Micronutrients /von 2018-07-12 / 2018 Jul;7(7)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution